SCHEMBL15840779

SCHEMBL15840779

Cc1ccc2nc(Nc3nc(CSc4ncccn4)cc(=O)[nH]3)nc(C)c2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 17/20 0.70
ALDH1A1 P00352 13/20 0.70
KMT2A Q03164 6/20 0.70
LMNA P02545 5/20 0.70
VSIR Q9H7M9 1/20 0.70
NPSR1 Q6W5P4 1/20 0.66
KDM4E B2RXH2 1/20 0.65
SMN1; SMN2 Q16637 6/20 0.61
CYP1A2 P05177 3/20 0.61
CYP3A4 P08684 3/20 0.61
CYP2C9 P11712 3/20 0.61
CYP2C19 P33261 3/20 0.61
HTT P42858 2/20 0.61
ALPL P05186 2/20 0.61
CYP2D6 P10635 1/20 0.61
XBP1 P17861 1/20 0.61
STAT3 P40763 1/20 0.61
PAX8 Q06710 1/20 0.60
MEN1 O00255 2/20 0.60
CREBBP Q92793 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840767 0.82 MAPT (1.00) MAPTALDH1A1KMT2ALMNAVSIR
SCHEMBL15840731 0.82 MAPT (0.74) MAPTALDH1A1KMT2ALMNAVSIR
SCHEMBL15840692 0.81 MAPT (0.73) MAPTALDH1A1KMT2ALMNAVSIR
SCHEMBL15840766 0.79 MAPT (1.00) MAPTALDH1A1KMT2ALMNAVSIR
SCHEMBL15840684 0.78 MAPT (0.64) MAPTALDH1A1KMT2ALMNAVSIR
SCHEMBL15840668 0.75 MAPT (1.00) MAPTALDH1A1KMT2ALMNAVSIR
SCHEMBL15840788 0.75 MAPT (1.00) MAPTALDH1A1KMT2ALMNAVSIR
SCHEMBL15840724 0.74 MAPT (0.67) MAPTALDH1A1KMT2ALMNAVSIR
SCHEMBL15840835 0.74 MAPT (0.81) MAPTALDH1A1KMT2ALMNAVSIR
SCHEMBL15840708 0.73 MAPT (1.00) MAPTALDH1A1KMT2ALMNAVSIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MAPT 1076/4885ALDH1A1 4348/4885KMT2A 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.